Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
4
×
life sciences
merck
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
diagnostics
indiana blog main
indiana top stories
novartis
pfizer
purdue pharma
roche
abbvie
adverum biotechnologies
alzheimer's disease
biogen
bristol-myers squibb
cancer
What
bio
drug
4
×
roundup
4
×
acquisitions
biggest
ceo
patients
pricing
advanced
advantages
albert
arrival
award
bar
bourla
brings
build
buy
cancer
company
company’s
crispr
daniel
data
death
debut
decades
dems
dyne’s
expect
future
gamble
gilead
given
immunotherapy
imports
longer
lung
maker
maps
Language
unset
unknown
Current search:
amgen
×
roundup
×
drug
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
